PRRUFOTCinactive

IMMUTEP Ltd

Healthcare·Oncology·Phase 3·Sydney, NSW, Australia
OncologyImmunology

IMMUTEP Ltd (PRRUF): 3 pipeline candidates · 4 clinical trials. Updated within the last hour.

7.2/10

BioSniper Score

2-factor signal · derived from public data

Cash RunwayN/A

N/A

Financial HealthN/A

N/A

Pipeline Maturity8.5

Lead: Phase 3

Pipeline Breadth5.9

3 candidates

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for IMMUTEP Ltdacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$73.7M

Cash

—

Quarterly Burn

—

Runway

—

Revenue

—

Pipeline (3 candidates)

DrugPhase
eftilagimod alfaPhase 3
eftilagimod alphaPhase 3
imp761Phase 1
4 clinical trials·CEO: Mr. Marc Voigt

Frequently asked questions

How many drug candidates are in IMMUTEP Ltd's pipeline?

IMMUTEP Ltd (PRRUF) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is IMMUTEP Ltd's lead drug candidate?

IMMUTEP Ltd's most advanced tracked candidate is eftilagimod alfa (Phase 3) for Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC).

What is IMMUTEP Ltd's market capitalization?

IMMUTEP Ltd's market capitalization is approximately $73.7M.

Who is the CEO of IMMUTEP Ltd?

Mr. Marc Voigt is the chief executive officer of IMMUTEP Ltd (PRRUF).

Get the full picture on IMMUTEP Ltd

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.

Start Free AnalysisBrowse Calendar